PCRX Pacira BioSciences, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Pacira BioSciences, Inc. (PCRX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Pacira BioSciences, Inc. (PCRX) (SEC CIK 1396814), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Innovative non-opioid pain therapies including EXPAREL, ZILRETTA, and iovera° for postsurgical and osteoarthritis pain management
- • New strategic plan "5x30" launched in Jan 2025 targeting 3M+ patients, double-digit revenue CAGR, 5% gross margin improvement, 5 clinical programs, 5 partnerships by 2030
Risk Factors
- • Ongoing patent litigation against WhiteOak and Qilu threatens exclusive rights to EXPAREL and ZILRETTA, risking loss of patent protection and regulatory exclusivity
- • Significant revenue concentration with EXPAREL at 79% and ZILRETTA at 16% of total 2025 revenue, exposing the company to commercial risks in these products
Management Discussion & Analysis
- • Revenue $726.4M, up 4% YoY from $701.0M; EXPAREL $575.1M (+5%), ZILRETTA $116.6M (-1%), iovera° $24.2M (+6%)
- • Gross margin 79% in 2025 vs 76% in 2024; cost of goods sold declined 12% to $149.7M
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: Settlement with eVenus ANDA Filers allows limited generic sales starting early 2030, volume capped rising from high single-digit to high thirties % by late 2030s
- • Updated risk: Patent infringement litigation expanded with new suits filed in Dec 2024, and new declaratory judgment action by eVenus ANDA Filers in 2025
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings announced Feb 26, 2026; period ended Dec 31, 2025
- • Full financial results contained in Exhibit 99.1 — key figures require review of attached press release
Annual Reports Archive10-K
AI-powered analysis of Pacira BioSciences, Inc. (PCRX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Pacira BioSciences, Inc. (PCRX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Pacira BioSciences, Inc. (PCRX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $666.8M | $675.0M | $701.0M | $726.4M |
| Operating Income | $60.0M | $87.7M | -$73.4M | $19.2M |
| Net Income | $15.9M | $42.0M | -$99.6M | $7.0M |
| Op. Margin | 9.0% | 13.0% | -10.5% | 2.6% |
| Net Margin | 2.4% | 6.2% | -14.2% | 1.0% |
| Balance Sheet | ||||
| Total Assets | $1.7B | $1.6B | $1.6B | $1.3B |
| Equity | $775.0M | $870.1M | $778.3M | $693.1M |
| ROE | 2.1% | 4.8% | -12.8% | 1.0% |
Source: XBRL financial data from Pacira BioSciences, Inc. (PCRX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 28, 2026 | — | — | |
8-K | Jan 8, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 30, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 3, 2021 | Jun 30, 2021 | — | |
10-Q | May 4, 2021 | Mar 31, 2021 | — | |
10-K | Mar 1, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest PCRX SEC filings in 2026?
Pacira BioSciences, Inc. (PCRX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did PCRX file its most recent 10-K annual report?
Pacira BioSciences, Inc. (PCRX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view PCRX 10-Q quarterly reports?
Pacira BioSciences, Inc. (PCRX)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every PCRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has PCRX filed recently?
Pacira BioSciences, Inc. (PCRX)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find PCRX insider trading activity (Form 4)?
SignalX aggregates every PCRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does PCRX file with the SEC?
Pacira BioSciences, Inc. (PCRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PCRX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Pacira BioSciences, Inc. (PCRX).
What is PCRX's SEC CIK number?
Pacira BioSciences, Inc. (PCRX)'s SEC CIK (Central Index Key) number is 1396814. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1396814 to look up all PCRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find PCRX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Pacira BioSciences, Inc. (PCRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Pacira BioSciences, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 55+ filings.